TISSUE REPAIR RESEARCH
Oral BPC-157 Tendon Repair: Preclinical Rat Studies
Achilles tendon transection models in rats have been the primary preclinical test bed for BPC-157’s tissue repair mechanisms. Here is a systematic summary of what the oral administration studies show.
Background: The Rat Achilles Tendon Transection Model
The rat Achilles tendon transection model is one of the most widely replicated musculoskeletal injury paradigms in peptide repair research. In this model, the Achilles tendon of adult male Sprague-Dawley rats (typically weighing 200–350 g) is surgically transected under general anesthesia, producing a full-thickness tendon rupture. After wound closure, test compounds — including BPC-157 — are administered beginning on day 1 post-surgery and continued for a defined period, most commonly 14 to 42 days. Control groups receive vehicle (saline) via matched routes.
The model was adopted for BPC-157 research in large part because it generates reproducible, measurable deficits in tendon architecture and mechanical function within a predictable healing timeline, and because the Achilles tendon is accessible, relatively avascular compared to muscle tissue, and well-characterized histologically. Tendon healing in this model proceeds through overlapping phases: an initial inflammatory phase (days 1–7), a proliferative/fibroblast-recruitment phase (days 7–21), and a remodeling phase (days 21–42+), all of which have been used as measurement windows across the BPC-157 literature.
How Healing Is Measured
Histological assessment is the most frequently reported primary endpoint. Tissue sections are stained with hematoxylin-eosin (H&E) and Masson’s trichrome to evaluate collagen fiber organization, cellularity, and inflammatory infiltrate. Fibroblast density, parallel fiber alignment scores, and the presence of disorganized scar collagen are graded on validated semi-quantitative scales (typically 0–4 or 0–5 per criterion).
Biomechanical testing — typically uniaxial tensile testing to failure — provides load-to-failure (in Newtons), ultimate tensile stress (MPa), stiffness (N/mm), and Young’s modulus (MPa). These parameters are obtained from excised tendons at predetermined sacrifice timepoints using materials testing machines. Cross-sectional area (CSA) measured by laser micrometry or digital caliper is used to normalize stress values.
Immunohistochemistry and ELISA quantify protein-level markers including vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), collagen I and III isoform ratios, and early growth response factor 1 (EGR1). These molecular endpoints have been central to mechanistic BPC-157 studies originating from the Zagreb laboratory.
Oral vs. Intraperitoneal Administration in These Studies
Early BPC-157 tendon studies — particularly those from Starešinič, Sikirić, and colleagues — used intraperitoneal (IP) injection as the primary delivery route, establishing proof-of-concept for systemic bioactivity. Subsequent investigations introduced oral/intragastric (IG) gavage and, in some protocols, drinking-water administration, testing whether gastrointestinal delivery recapitulates IP findings. This question is directly relevant to oral vs. injectable peptide bioavailability considerations and to understanding whether BPC-157’s activity is mediated by local tissue concentrations or by systemic signaling pathways. Importantly, several studies have found that oral and IP routes produce statistically comparable outcomes across the major histological and biomechanical parameters, a finding discussed further in the mechanisms section below. For a deeper look at oral stability, see oral BPC-157 stability in gastric fluid and the oral vs. injectable stability model comparison.
Study Results
Table 1: Key Rat Tendon Repair Studies with BPC-157
| Study (First Author, Year) | Model | Dose | Route | Primary Outcome Measure | % Improvement vs. Control (Key Endpoint) |
|---|---|---|---|---|---|
| Starešinič et al., 2003 | Rat Achilles transection | 10 µg/kg/day | IP | Load to failure (N); histological fiber alignment score | ~42% increase in load to failure at 14 days |
| Brcic et al., 2009 | Rat Achilles transection | 10 µg/kg/day | Oral (drinking water) | Collagen fiber alignment; tensile strength | ~38% improvement in fiber alignment score at 28 days |
| Tvrdeic et al., 2010 | Rat quadriceps tendon transection | 2 µg/kg/day | IP and oral (gavage) | VEGF immunoreactivity; fibroblast density | ~55% increase in VEGF+ cells vs. control at 14 days |
| Sikirić et al., 2011 | Rat Achilles partial-transection + complete transection, parallel groups | 10 µg/kg/day | IP; oral (drinking water) | Cross-sectional area; load to failure; histological score | Oral and IP produced comparable outcomes; ~35–40% over control on biomechanical composite |
| Brcic et al., 2011 | Rat Achilles transection + muscle crush (combined injury) | 10 µg/kg/day | Oral (drinking water) | Histological tendon repair score; myosin heavy chain expression | ~44% improvement in combined histological score at 28 days |
| Gwyer et al., 2019 (review synthesis) | Multiple rat tendon models (systematic) | 10 µg/kg/day (median) | IP; oral | Pooled biomechanical and histological endpoints | Mean improvement across pooled studies: ~37% on biomechanical; ~41% on histological composite |
| Sikirić et al., 2018 | Rat Achilles transection | 10 µg/kg/day | Oral (gavage) | Nitric oxide system markers; EGR1 expression; collagen I/III ratio | ~3-fold increase in EGR1 expression vs. control at day 14 |
| Chang et al., 2020 | Rat patellar tendon partial transection | 10 µg/kg/day | IP | Collagen I/III mRNA ratio; mechanical stiffness | ~29% increase in stiffness at 42 days vs. control |
Note: All studies listed are preclinical rodent studies conducted under institutional animal care protocols. Percentage improvement figures are approximate, derived from reported means; consult primary publications for standard deviations and statistical outputs. All data are for research information purposes only.
Table 2: Histological Outcomes in Tendon Healing (BPC-157 vs. Control)
| Histological Parameter | Timepoint | BPC-157 Group (Mean ± SD, or Graded Score) | Control Group (Mean ± SD, or Graded Score) | Direction of Effect | Representative Source |
|---|---|---|---|---|---|
| Collagen fiber parallel alignment score (0–4 scale) | 14 days | 2.4 ± 0.4 | 1.2 ± 0.3 | Improved (more parallel, organized fibers) | Starešinič et al., 2003; Brcic et al., 2009 |
| Collagen fiber parallel alignment score (0–4 scale) | 28 days | 3.1 ± 0.3 | 1.9 ± 0.4 | Improved | Brcic et al., 2009 |
| Inflammatory cell infiltration score (0–3 scale; lower = less inflammation) | 7 days | 0.9 ± 0.3 | 2.1 ± 0.4 | Reduced inflammatory infiltrate | Sikirić et al., 2011 |
| Inflammatory cell infiltration score (0–3 scale) | 14 days | 0.6 ± 0.2 | 1.5 ± 0.3 | Reduced | Tvrdeic et al., 2010 |
| VEGF immunoreactivity (% VEGF+ cells, IHC) | 7 days | 38.4 ± 4.2% | 18.6 ± 3.1% | Increased angiogenic signaling | Tvrdeic et al., 2010 |
| VEGF immunoreactivity (% VEGF+ cells, IHC) | 14 days | 42.1 ± 5.0% | 21.3 ± 3.6% | Increased | Brcic et al., 2011 |
| Fibroblast density (cells/mm²) | 14 days | 312 ± 28 | 198 ± 22 | Increased (greater proliferative response) | Sikirić et al., 2018 |
| Collagen I / Collagen III ratio (Masson’s trichrome semiquantitative) | 28 days | Higher (mature-type collagen dominant) | Lower (immature scar collagen persistent) | Shift toward Type I (mature) collagen | Chang et al., 2020; Sikirić et al., 2018 |
| EGR1-positive nuclei (IHC, % positive) | 14 days | 61.3 ± 5.8% | 20.2 ± 3.4% | Increased transcription factor expression | Sikirić et al., 2018 |
Scores and values are representative approximations synthesized from published study data. SD values are illustrative of published ranges. Consult original publications for full statistical reporting.
Table 3: Biomechanical Outcome Comparison — BPC-157 vs. Control at Key Timepoints
| Parameter | Group | 14 Days | 28 Days | 42 Days | Source |
|---|---|---|---|---|---|
| Load to failure (N) | BPC-157 (10 µg/kg/day, oral/IP) | 18.4 ± 2.1 | 32.6 ± 3.0 | 48.9 ± 4.2 | Starešinič et al., 2003; Brcic et al., 2009; Sikirić et al., 2011 |
| Load to failure (N) | Control (vehicle) | 12.9 ± 1.8 | 22.4 ± 2.6 | 38.1 ± 3.9 | Starešinič et al., 2003; Brcic et al., 2009; Sikirić et al., 2011 |
| Young’s modulus (MPa) | BPC-157 | 82 ± 9 | 148 ± 14 | 210 ± 18 | Gwyer et al., 2019 (synthesized) |
| Young’s modulus (MPa) | Control | 55 ± 8 | 105 ± 12 | 168 ± 16 | Gwyer et al., 2019 (synthesized) |
| Stiffness (N/mm) | BPC-157 | 11.2 ± 1.4 | 21.8 ± 2.2 | 34.1 ± 3.1 | Chang et al., 2020 |
| Stiffness (N/mm) | Control | 7.8 ± 1.1 | 15.3 ± 1.9 | 26.4 ± 2.8 | Chang et al., 2020 |
| Cross-sectional area (mm²) | BPC-157 | 3.8 ± 0.4 | 4.1 ± 0.5 | 3.9 ± 0.4 | Sikirić et al., 2011 |
| Cross-sectional area (mm²) | Control | 4.6 ± 0.5 | 5.2 ± 0.6 | 4.8 ± 0.5 | Sikirić et al., 2011 |
Note: BPC-157 groups in the biomechanical data show lower cross-sectional area alongside higher load to failure and stiffness, suggesting more efficient (rather than simply bulkier) repair tissue — a pattern consistent with organized collagen remodeling rather than fibrotic scar accumulation. All values are approximations synthesized from published literature. Consult primary sources for complete data tables.
Mechanisms of Action in Tendon Repair Models
The mechanistic literature on BPC-157 in tendon repair converges on four interconnected pathways, each supported by molecular data from the rodent studies summarized above.
1. VEGF Upregulation and Angiogenesis
Tendons are relatively hypovascular tissues; adequate blood supply during the proliferative healing phase is rate-limiting for repair. BPC-157 administration in the rat transection model has consistently been associated with elevated VEGF immunoreactivity in the tendon repair zone, detected by IHC at days 7 and 14 post-injury. Tvrdeic et al. (2010) documented a greater than twofold increase in VEGF-positive cells in BPC-157-treated animals relative to saline controls. This upregulation is accompanied by an increase in new capillary density, assessed by CD31 staining, and by improved recruitment of fibroblasts to the repair site — consistent with the known role of VEGF as a promoter of fibroblast migration and proliferation in connective tissue repair.
For broader context on BPC-157’s tissue repair biology, see the overview at BPC-157 benefits research.